Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts

Nature Communications

Volumn 6, Issue , 2015, Pages

  Albrengues, Jean ^a   Bertero, Thomas ^a   Grasset, Eloise ^a   Bonan, Stephanie ^a   Maiel, Majdi ^a   Bourget, Isabelle ^a   Philippe, Claude ^a   Herraiz Serrano, Cecilia ^b   Benamar, Samia ^c   Croce, Olivier ^a   Sanz Moreno, Victoria ^b   Meneguzzi, Guerrino ^a   Feral, Chloe C ^a   Cristofari, Gael ^a   Gaggioli, Cedric ^a  

^a UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3B; E1A ASSOCIATED P300 PROTEIN; HISTONE ACETYLTRANSFERASE; JANUS KINASE 1; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT3 PROTEIN; CYTOKINE; NEUTRALIZING ANTIBODY;

CANCER; CARCINOGEN; CELL ORGANELLE; DNA; GENE EXPRESSION; PHENOTYPE; TUMOR;

ANIMAL EXPERIMENT; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CONTROLLED STUDY; EPIGENETICS; FEMALE; FIBROBLAST; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN ACETYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CARCINOGENESIS; CELL CULTURE; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; PHYSIOLOGY; RNA INTERFERENCE;

ANIMALS; ANTIBODIES, NEUTRALIZING; CARCINOGENESIS; CELLS, CULTURED; CYTOKINES; EPIGENOMICS; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; RNA INTERFERENCE;

EID: 84950129821     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10204     Document Type: Article

References (63)

1. Calvo, F. and Sahai, E. Cell communication networks in cancer invasion. Curr. Opin. Cell Biol. 23, 621-629 (2011).
2. Erez, N., Truitt, M., Olson, P., Arron, S. T. and Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17, 135-147 (2010).
3. Kalluri, R. and Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer. 6, 392-401 (2006).
4. Boyd, N. F. et al. Mammographic density and the risk and detection of breast cancer. N. Engl. J. Med. 356, 227-236 (2007).
5. Hendrix, A., Gespach, C., Bracke, M. and De Wever, O. The tumor ecosystem regulates the roads for invasion and metastasis. Clin. Res. Hepatol. Gastroenterol. 35, 714-719 (2011).
6. Navab, R. et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc. Natl Acad. USA 108, 7160-7165 (2011).
7. Shi, M. et al. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J. Gastroenterol. 18, 840-846 (2012).
8. Takahashi, Y. et al. Fibrous stroma is associated with poorer prognosis in lung squamous cell carcinoma patients. J. Thorac. Oncol. 6, 1460-1467 (2011).
9. Gaggioli, C. et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 9, 1392-1400 (2007).
10. Goetz, J. G. et al. Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 146, 148-163 (2011).
11. Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891-906 (2009).
12. Bechtel, W. et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat. Med. 16, 544-550 (2010).
13. Cox, T. R. and Erler, J. T. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis. Model. Mech. 4, 165-178 (2011).
14. Wynn, T. A. and Ramalingam, T. R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 18, 1028-1040 (2012).
15. Sanz-Moreno, V. et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 20, 229-245 (2011).
16. Albrengues, J. et al. LIF mediates proinvasive activation of stromal fibroblasts in cancer. Cell Rep. 7, 1664-1678 (2014).
17. Frank, D. A. STAT signaling in the pathogenesis and treatment of cancer. Mol. Med. 5, 432-456 (1999).
18. Rawlings, J. S., Rosler, K. M. and Harrison, D. A. The JAK/STAT signaling pathway. J. Cell Sci. 117, 1281-1283 (2004).
19. Zhang, Q. et al. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc. Natl Acad. USA 102, 6948-6953 (2005).
20. Wieczorek, M., Ginter, T., Brand, P., Heinzel, T. and Kramer, O. H. Acetylation modulates the STAT signaling code. Cytokine Growth Factor Rev. 23, 293-305 (2012).
21. Yuan, Z. L., Guan, Y. J., Chatterjee, D. and Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307, 269-273 (2005).
22. Lee, H. et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc. Natl Acad. USA 109, 7765-7769 (2012).
23. Gopalakrishnan, S., Van Emburgh, B. O. and Robertson, K. D. DNA methylation in development and human disease. Mutat. Res. 647, 30-38 (2008).
24. Counts, J. L. and Goodman, J. I. Alterations in DNA methylation may play a variety of roles in carcinogenesis. Cell 83, 13-15 (1995).
25. Das, P. M. and Singal, R. DNA methylation and cancer. J. Clin. Oncol. 22, 4632-4642 (2004).
26. Feinberg, A. P. The epigenetics of cancer etiology. Semin. Cancer Biol. 14, 427-432 (2004).
27. Jiang, L. et al. Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res. 68, 9900-9908 (2008).
28. Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257-272 (2011).
29. Kaneda, M. et al. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature 429, 900-903 (2004).
30. Albrengues, J., Meneguzzi, G. and Gaggioli, C. Analysis of Collective Invasion of Carcinoma Cells in a 3D Organotypic Model. Methods Mol. Biol. 961, 243-252 (2013).
31. Chen, T. Mechanistic and functional links between histone methylation and DNA methylation. Progress Mol. Biol. Transl. Sci. 101, 335-348 (2011).
32. Rane, S. G. and Reddy, E. P. Janus kinases: components of multiple signalling pathways. Oncogene 19, 5662-5679 (2000).
33. Starr, R. and Hilton, D. J. Negative regulation of the JAK/STAT pathway. BioEssays 21, 47-52 (1999).
34. Sengupta, T. K., Schmitt, E. M. and Ivashkiv, L. B. Inhibition of cytokines and JAK-STAT activation by distinct signalling pathways. Proc. Natl Acad. USA 93, 9499-9504 (1996).
35. Wu, C., Sun, M., Liu, L. and Zhou, G. W. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306, 1-12 (2003).
36. Calvo, F. et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat. Cell Biol. 15, 637-646 (2013).
37. Costea, D. E. et al. Identification of two distinct carcinoma-associated fibroblast subtypes with differential tumor-promoting abilities in oral squamous cell carcinoma. Cancer Res. 73, 3888-3901 (2013).
38. Satoyoshi, R., Kuriyama, S., Aiba, N., Yashiro, M. and Tanaka, M. Asporin activates coordinated invasion of scirrhous gastric cancer and cancer-associated fibroblasts. Oncogene 34, 650-660 (2015).
39. Bowman, T., Garcia, R., Turkson, J. and Jove, R. STATs in oncogenesis. Oncogene 19, 2474-2488 (2000).
40. Yu, H., Pardoll, D. and Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798-809 (2009).
41. Rebouissou, S. et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200-204 (2009).
42. Tefferi, A. JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J. 13, 366-371 (2007).
43. Lederle, W. et al. IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines. Int. J. Cancer 128, 2803-2814 (2011).
44. Bhattacharyya, S. et al. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum. 52, 1248-1258 (2005).
45. Banerjee, J. et al. A reciprocal role of prostate cancer on stromal DNA damage. Oncogene 33, 4924-4931 (2014).
46. Bian, E. B. et al. DNMT1-mediated PTEN hypermethylation confers hepatic stellate cell activation and liver fibrogenesis in rats. Toxicol. Appl. Pharmacol. 264, 13-22 (2012).
47. Komatsu, Y. et al. Global analysis of DNA methylation in early-stage liver fibrosis. BMC Med. Genomics 5, 5 (2012).
48. Sanders, Y. Y. et al. Thy-1 promoter hypermethylation: a novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 39, 610-618 (2008).
49. Takenaka, K. et al. Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis. Mol. Med. Rep. 2, 73-80 (2009).
50. Zeisberg, E. M. and Zeisberg, M. The role of promoter hypermethylation in fibroblast activation and fibrogenesis. J. Pathol. 229, 264-273 (2013).
51. Chim, C. S., Fung, T. K., Cheung, W. C., Liang, R. and Kwong, Y. L. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103, 4630-4635 (2004).
52. Oka, T. et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 62, 6390-6394 (2002).
53. Ghosh, A. K. and Varga, J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J. Cell Physiol. 213, 663-671 (2007).
54. Ohbayashi, N. et al. LIF- and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation. Biol. Pharm. Bull. 30, 1860-1864 (2007).
55. Yao, T. P. et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93, 361-372 (1998).
56. Iyer, N. G., Ozdag, H. and Caldas, C. p300/CBP and cancer. Oncogene 23, 4225-4231 (2004).
57. Christman, J. K. 5-Azacytidine and 5-aza-2-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21, 5483-5495 (2002).
58. Joeckel, T. E. and Lubbert, M. Clinical results with the DNA hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Sem. Hematol. 49, 330-341 (2012).
59. Bhutani, N., Burns, D. M. and Blau, H. M. DNA demethylation dynamics. Cell 146, 866-872 (2011).
60. Tampe, B. et al. Tet3-mediated hydroxymethylation of epigenetically silenced genes contributes to bone morphogenic protein 7-induced reversal of kidney fibrosis. J. Am. Soc. Nephrol. 25, 905-912 (2014).
61. Hesson, L. B. et al. Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure. PLoS Genet. 9, e1003636 (2013).
62. Kloda, J. M., Dean, P. D., Maddren, C., MacDonald, D. W. and Mayes, S. Using principle component analysis to compare genetic diversity across polyploidy levels within plant complexes: an example from British Restharrows (Ononis spinosa and Ononis repens). Heredity 100, 253-260 (2008).
63. Kumaki, Y., Oda, M. and Okano, M. QUMA: quantification tool for methylation analysis. Nucleic Acids Res. 36, W170-W175 (2008).